United States Epigenetics Market

Market Overview

The United States epigenetics market was valued at USD 692.68 million in 2023. It is estimated to reach USD 2,593.63 million by 2032, growing at a CAGR of 15.80% during the forecast period (2024–2032). The rising cases of chronic diseases like CVDs, cancer, neurodegenerative conditions, etc, primarily drive the United States epigenetics market. The burden of these chronic diseases further increases with a surge in the aging population, subsequently boosting the US epigenetics market. Moreover, the regional market players are collaborating with each other to enhance their market share, thereby creating opportunities for market growth.

Highlights

• Reagents and kits dominate the product segment
• Oncology dominates the application segment
• Pharmaceutical and biotechnology companies dominated the end-user segment

Market Dynamics

The United States Epigenetics Market Drivers:

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic illnesses like cancer, cardiovascular disorders, and neurodegenerative conditions is a major driver of the US epigenetics market. For instance, the CDC estimates that approximately 60% of adults in the United States are currently living with a chronic illness, such as diabetes, heart disease, or cancer. Chronic illnesses are among the primary causes of mortality in the United States, with heart disease and cancer collectively contributing to approximately 38 percent of all fatalities.

As traditional treatment approaches often fall short, there is a growing demand for innovative diagnostic tools and therapeutic strategies that target epigenetic alterations. This demand is further amplified by the aging population, which is more exposed to chronic illnesses. Therefore, substantial investments are being funneled into epigenetic research and product development, aiming to provide more effective, personalized treatment options that address the underlying epigenetic causes of chronic conditions.

The United States Epigenetics Market Restraint:

Technical Limitations

The expense and accessibility of cutting-edge tools necessary for thorough epigenetic research present formidable obstacles. Next-generation sequencing (NGS) and high-throughput systems for epigenome-wide analysis are examples of cutting-edge technologies whose high cost prevents them from being widely used, especially at research institutes with limited funding. The expertise required to operate these sophisticated devices and assess the data they generate further restricts their accessibility. It impedes the widespread application of epigenetics in clinical settings and other businesses.

Furthermore, accurately recording epigenetic changes in real-time is difficult because epigenetic markers are subject to change in response to internal and external stimuli. Understanding the dynamic nature of epigenetic modifications requires longitudinal investigations, which are time-consuming, costly, and logistically difficult to do, particularly in large populations. Thus, all such factors are estimated to restrict the US epigenetics market growth.

The United States Epigenetics Market Opportunities:

Strategic Collaborations by the Key Players

The key players in the US region are collaborating to integrate epigenetics solutions into their portfolios. For instance, in February 2024, Cardio Diagnostics Holdings, Inc., a precision cardiovascular medicine company that is AI-driven, announced that the resTOR Longevity Clinic, a concierge clinic in Houston, will incorporate Cardio Diagnostics' solutions into its battery of tests for new patients. This partnership represents a significant milestone for Cardio Diagnostics, as resTOR will be the first longevity clinic in the United States to integrate Cardio Diagnostics' cutting-edge blood-based epigenetic tests for cardiovascular disease, Epi+Gen CHD and PrecisionCHD, into its testing regimen for new patients. This is estimated to create opportunities for the growth of the US epigenetics market.

Regional Analysis

The US epigenetics market is being driven by factors like extensive R&D activities, the presence of key market players, and supportive regulatory frameworks. In the US, the flourishing prevalence of chronic diseases, robust healthcare infrastructure, and favorable reimbursement policies drive the adoption of epigenetic technologies. Moreover, the rising aging population is further accelerating the US epigenetics market. For instance, projections indicate that the number of Americans aged 65 and older will surpass 95 million by 2060, a significant increase from the 52 million reported in 2018. Moreover, there has also been a rise in investment in the firms involved in the development of epigenetics therapeutics.

For instance, in January 2024, Moonwalk Biosciences, a genomic medicine company that is at the forefront of precision epigenetic medications in San Fransisco, announced the successful completion of USD 57 million in seed and Series A financing. The financing will facilitate the ongoing development of Moonwalk's epigenetic profiling and engineering technology platform, as well as the advancement of its pipeline of epigenetic therapeutics toward the clinic. Moonwalk's objective is to reprogram cells to their healthy state by targeting the epigenetic code, the genome software. This profoundly enables a new approach to the discovery and development of therapies. Thus, the above factors are anticipated to boost the United States epigenetics market growth.

Segmental Analysis

The United States epigenetics market is segmented by product, application, and end-user.

Based on product, the US epigenetics market is divided into instruments, reagents and kits, enzymes, software, and services. 

The reagents and kits segment dominates the global epigenetics market and is projected to exhibit a CAGR of 16.3% over the forecast period. The reagents and kits segment encompasses essential tools for epigenetic research, including DNA methylation kits, chromatin immunoprecipitation (ChIP) kits, and histone modification antibodies. These products facilitate accurate and efficient analysis of epigenetic modifications, driving advancements in both basic research and clinical applications.

Based on application, the United States epigenetics market is segmented into oncology, autoimmune diseases, metabolic diseases, CNS/pain diseases, cardiovascular diseases, and others. 

The oncology segment is estimated to own the highest market share and grow at a CAGR of 16.1% over the forecast period. The oncology segment leverages epigenetic insights to develop novel cancer diagnostics and therapeutics. Epigenetic modifications like DNA methylation and histone modification are crucial in cancer development, making them targets for innovative treatments and biomarkers for early cancer detection, prognosis, and personalized medicine.

Based on end-users, the epigenetics market for united states is bifurcated into pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROS), and others. 

The pharmaceutical and biotechnology companies contributed to the largest market share and is anticipated to exhibit at a CAGR of 16.5% over the forecast period. Pharmaceutical and biotechnology companies are key players in the epigenetics market, focusing on the development of epigenetic drugs and therapies. These companies invest heavily in R&D to discover new epigenetic targets and create therapies for diseases such as cancer, neurological disorders, and autoimmune diseases.

Recent Developments

• November 2023-Tune Therapeutics, a groundbreaking business specializing in epigenome editing, revealed its ongoing efforts to develop a novel and potentially curative method for addressing persistent HBV infection.